Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 647-654

  Khan, A Nazmul H ^a   Gregorie, Christopher J ^a   Tomasi, Thomas B ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antigen presentation; Epigenetic regulation; Histone deacetylase inhibitor; Melanoma; MHC class I

Indexed keywords

ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN DERIVATIVE; TAP2 PROTEIN; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DNA MODIFICATION; EPIGENETICS; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MELANOMA; MEMBRANE TRANSPORT PROTEINS; MICE; MULTIENZYME COMPLEXES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 43149097365     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0402-4     Document Type: Article

References (43)

1. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS (2004) Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 228:130-137
2. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65:6321-6329
3. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116
4. Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL (2005) Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun 73:6620-6628
5. Chang C-C, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S (2006) Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281:18763-18773
6. Chou S-D, Khan ANH, Magner WJ, Tomasi TB (2005) Histone acetylation regulates the cell type specific CIITA promoter, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17:1483-1494
7. Ducasse M, Brown MA (2006) Epigenetic aberrations and cancer. Mol Cancer. http://www.molecular-cancer.com/content/5/1/60
8. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Uzi Gileadi U, Vincenzo Cerundolo V, Man S (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167:5420-5428
9. Feenstra M, Rozemuller E, Duran K, Stuy I, van den Tweel J, Slootweg P, de Weger R, Tilanus M (1999) Mutation in the beta-2 m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol 8:697-706
10. Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M (2003) Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 105:430-431
11. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM (1996) Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:429-435
12. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol Med Today 5:178-186
13. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17-27
14. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080
15. Jimenez P, Canton J, Concha A, Cabrera T, Fernández M, Real LM, García A, Serrano A, Garrido F, Ruiz-Cabello F (2000) Microsatellite instability analysis in tumor with different mechanisms for total loss of HLA expression. Cancer Immunol Immunother 48:684-90
16. Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-18
17. Khan ANH, Magner WJ, Tomasi TB (2004) An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 53:748-754
18. Komatsu Y, Hayashi H (1998) Histone deacetylase inhibitors up-regulate the expression of cell surface MHC class I molecules in B16/BL6 cells. J Antibiot 51:89-91
19. Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H (2001) Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61:4459-4466
20. Lentschat A, Karahashi H, Michelsen KS, Thomas LS, Zhang W, Vogel SN, Arditi M (2005) Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages. J Immunol 174:4252-4261
21. Li H, Ou X, Xiong J, Wang T (2006) HPV16E7 mediates HDAC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun 349:1315-1321
22. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397-413
23. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65:7926-7933
24. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf, Ferrone S (2006) Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25:2873-2884
25. Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96:3847-3856
26. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017-7024
27. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497-1511
28. Mora-García ML, Duenas-González A, Hernández-Montes J, Cruz-Hernández ED, Pérez-Cárdenas E, Weiss-Steider B, Santiago-Osorio E, Ortíz-Navarrete VF, Rosales VH, Cantú D, Lizano-Soberón M, Rojo-Aguilar MP, Monroy-García A (2006) Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med 4:55
29. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S (2006) HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66:9281-9289
30. Osborne A, Zhang H, Yang WM, Seto E, Blanck G (2001) Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 21:6495-6506
31. Ou J-N, Torrisani J, Unterberger A, Provençal N, Shikimi K, Karimi M, Ekström TJ, Szyf M (2007) Histone deacetylase inhibitor trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 73:1297-1307
32. Raffaghello L, Prigione I, Bocca P, Morandi, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V (2005) Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24:4634-4644
33. Romero JM, Jimenez P, Cabrera T, Cózar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 113:605-610
34. Schoenberger SP, Jonges LE, Mooijaart RJ, Hartgers F, Toes RE, Kast WM, Melief CJ, Offringa R (1998) Efficient direct priming of tumor specific cytotxic T lymphocyte in vivo by an engineered APC. Cancer Res 58:3094-3100
35. Schoenhals GJ, Krishna RM, Grandea AG 3rd, Spies T, Peterson PA, Yang Y, Früh K (1999) Retention of empty MHC class I molecules by Tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J 18:743-753
36. Seliger B, Harders C, Lohmann S, Momberg F, Urlinger S, Tampe R, Huber C (1998) Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol 28:122-133
37. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455-464
38. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C (2000) Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56:327-336
39. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C (2001) Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61:1095-1099
40. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment. Int J Cancer 94:243-251
41. Tomasi TB, Magner WJ, Khan ANH (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55:1159-1184
42. Zhao B, Hou S, Ricciardi RP (2003) Chromatin repression by COUP-TFII and HDAC dominates activation by NF-kappaB in regulating major histocompatibility complex class I transcription in adenovirus tumorigenic cells. Virology 306:68-76
43. Zika E, Greer SF, Zhu X-S, Ting JP (2003) Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol 23:3091-3102